AI-designed drug shows early promise for lung fibrosis patients in clinical trial
Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial.…